Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 13;8(2):e010838. doi: 10.1161/JAHA.118.010838

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Effects of PCSK9 inhibition on microglial count after cardiac I/R injury. A, Percentage of CD11b⁺/CD45⁺ microglia of the brains. B, Percentage of CD11b⁺/CD45^+high microglia of the brains. C, Representative flow cytometry images of microglial count. I/R, ischemia/reperfusion; CD, cluster of differentiation; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; Control, rat group with no surgical intervention; PCSK9i, rats group with no intervention and treated with PCSK9i for 180 minutes; Sham, rat group with open chest surgery; Vehicle, rats treated with vehicle at 15 minutes before cardiac I/R; Pretreatment, rats treated with PCSK9i at 15 minutes before cardiac I/R; Ischemia, rats treated with PCSK9i at 15 minutes during ischemic period; Reperfusion, rats treated with PCSK9i at the onset of reperfusion period (n=4–10 per group). *P<0.05 vs control, PCSK9i, and sham, ^† P<0.05 vs vehicle.